Omeros (NASDAQ:OMER) Given Overweight Rating at Cantor Fitzgerald

by · The Cerbat Gem

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued on Wednesday, Marketbeat reports. They currently have a $22.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 16.53% from the company’s previous close.

Several other research firms also recently commented on OMER. Weiss Ratings raised shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Get Our Latest Stock Report on OMER

Omeros Stock Down 3.8%

OMER opened at $18.88 on Wednesday. The firm has a 50-day simple moving average of $18.12 and a two-hundred day simple moving average of $13.72. Omeros has a 52 week low of $4.05 and a 52 week high of $21.24. The company has a market capitalization of $1.37 billion, a PE ratio of 14.75 and a beta of 2.57.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, sell-side analysts expect that Omeros will post -0.37 earnings per share for the current year.

Insider Buying and Selling at Omeros

In related news, Director Thomas Cable sold 15,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the transaction, the director owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Cancelmo sold 25,000 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares of the company’s stock, valued at approximately $3,708. The trade was a 99.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 105,906 shares of company stock worth $1,989,705 in the last 90 days. 10.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OMER. GK Wealth Management LLC bought a new position in shares of Omeros in the 3rd quarter valued at about $65,000. State Street Corp lifted its holdings in shares of Omeros by 20.9% in the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock valued at $22,062,000 after acquiring an additional 400,331 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Omeros in the 2nd quarter valued at about $138,000. Squarepoint Ops LLC bought a new position in shares of Omeros in the 2nd quarter valued at about $523,000. Finally, Arizona State Retirement System bought a new position in shares of Omeros in the 2nd quarter valued at about $179,000. Institutional investors own 48.79% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Featured Articles